

Thursday,18 April 2019

BUY Upgrade

Last price (IDR)	2,520
Target Price (IDR)	3,400
Upside/Downside	+34.9%
Previous Target Price (IDR)	2,800

Stock Statistics

Sector	CONSUMER
Bloomberg Ticker	KINO IJ
No of Shrs (mn)	1,429
Mkt. Cap (IDRbn/USDmn)	3,600/256
Avg. daily T/O (IDRbn/USDmn)	1.3/0.1

Major shareholders (%)

PT KINO INVESTINDO	69.5
DBSSG S/A NUSANTARA FMCG LIMITED	10.7
Estimated free float	10.5

KINO relative to JCI Index



Source: Bloomberg

Natalia Sutanto (62-21) 2955 5888 ext.3508 natalia.sutanto@danareksa.com

Kino Indonesia (KINO IJ)

Enticing turnaround story

KINO offers investors an enticing turnaround story thanks to successful distribution revamping which puts the company in a better position to tap segmented niche markets in consumer products. All in all, we believe the improving performance will translate into strong FY19 earnings growth of 25% yoy. Upgrade to BUY.

Expect the solid growth to continue. KINO recorded much better sales performance in 2018 buoyed by successful distribution revamping. This year, the company is optimistic that the improvements will continue, especially with the support from several new products which were launched last year: (1) Lola Remedios — a herbal remedy entering the Philippines' market in November 2018; (2) Sasha Toothpaste — a halal product targeting the Muslim community with plans for more aggressive promotions starting in 2Q19 and (3) pet food—with its Pro Diet and Pro Balance brands. Furthermore, this year's food revenues will get a timely boost from the full consolidation of Morinaga Kino Indonesia (MKI).

FY19F earnings estimated to grow 25% yoy. Following the release of strong FY18 results, we estimate that KINO's FY19 revenues will grow briskly by 20% yoy to IDR4.3tn. According to the management, its personal care products – including its Ellips brand (Hair Vitamin) – are enjoying strong demand in both local and export markets. To cater to the growing demand, additional capacity is expected to come onstream in 2Q-3Q19. For beverages, its products are continuing to gain market share - approaching that of its closest competitor Cap Badak (in FY18, the revenues growth of KINO's beverages reached 25% yoy). To promote its new products, we believe that the FY19F A&P expenses will be little changed from those incurred in FY18. Against this backdrop, we revise up our FY19F earnings estimate by 7.8% to IDR188bn (+25% yoy).

Upgrade to BUY. Based on our survey, Sasha toothpaste is already available in major minimarkets at competitive prices. For pet food, Nestle Purina is the leader in Indonesia's market - with 29% market share, followed by Mars Pedigree (26%) – based on data from Mordor Intelligence. All in all, we like the stock for its attractive valuation of 18.5x FY19F with FY19F earnings growth that is estimated to surpass that of the sector. Taking into account our new forecast, we upgrade our recommendation to BUY with a higher TP of IDR3,400 (FY19F PE 25.9x) – based on DCF valuation (WACC 11.6%, TG 5%).


Key Financials

Year to 31 Dec	2017A	2018A	2019F	2020F	2021F
Revenue (IDRbn)	3,161	3,612	4,342	4,992	5,623
EBITDA (IDRbn)	212	275	339	407	527
EBITDA Growth (%)	(21.4)	29.8	23.2	20.0	29.5
Net profit (IDRbn)	110	150	188	232	315
EPS (IDR)	77.3	105.1	131.4	162.6	220.5
EPS growth (%)	(38.9)	35.9	25.1	23.7	35.6
BVPS (IDR)	1,412.6	1,511.3	1,621.7	1,758.0	1,946.0
DPS (IDR)	25.0	27.0	21.0	26.3	32.5
PER (x)	31.4	23.1	18.5	14.9	11.0
PBV (x)	1.7	1.6	1.5	1.4	1.2
Dividend yield (%)	1.0	1.1	0.9	1.1	1.3
EV/EBITDA (x)	17.4	13.9	10.9	9.3	7.1

Source: KINO, Danareksa Estimates



Exhibit 1. Revenues and Growth




Source: Company, Danareksa Sekuritas estimates

Exhibit 3. Margins




Source: Company, Danareksa Sekuritas estimates

Exhibit 5. Revenue by divisions




Source: Company, Danareksa Sekuritas estimates

Exhibit 2. Net Profits and Growth




Source: Company, Danareksa Sekuritas estimates

Exhibit 4. Gearing Level



Source: Company, Danareksa Sekuritas estimates

Exhibit 6. Opex to revenue



Source: Company, Danareksa Sekuritas estimates



Exhibit 7. Inventory and receivable days





Exhibit 8. Payable days and Cash conversion cycle



Source: Company, Danareksa Sekuritas estimates

Source: Company, Danareksa Sekuritas estimates





Source: Company, Danareksa Sekuritas estimates



Exhibit 10. Earnings revision

	Previo	Previous		New		Changes	
	2019	2020	2019	2020	2019	2020	
Revenue	3,889	4,407	4,342	4,992	11.7%	13.3%	
Gross profit	1,746	1,944	1,959	2,246	12.2%	15.6%	
Operating profit	291	317	296	359	1.8%	13.5%	
Net profit	174	194	188	232	7.8%	19.7%	
Gross margin	44.9%	44.1%	45.1%	45.0%			
Operating margin	7.5%	7.2%	6.8%	7.2%			
Net margin	4.5%	4.4%	4.3%	4.7%			

Source: Company, Danareksa Sekuritas estimates

Exhibit 11. Sasha toothpaste





Source: Shopee, Bukalapak *Retail selling prices in Alfamart and Indomaret starting from IDR12,500/piece



Exhibit 12. Income Statement

Year to 31 Dec (IDRbn)	2017A	2018A	2019F	2020F	2021F
Revenue	3,161	3,612	4,342	4,992	5,623
COGS	(1,830)	(1,968)	(2,383)	(2,746)	(3,079)
Gross profit	1,330	1,643	1,959	2,246	2,544
EBITDA	212	275	339	407	527
Oper. profit	187	236	296	359	475
Interest income	17	11	14	15	19
Interest expense	(70)	(56)	(57)	(62)	(70)
Forex Gain/(Loss)	(1)	0	0	0	0
Income From Assoc. Co's	(4)	(14)	0	0	0
Other Income (Expenses)	13	23	(3)	(2)	(2)
Pre-tax profit	141	200	251	310	420
Income tax	(31)	(50)	(63)	(78)	(105)
Minority interest	1	0	0	0	0
Net profit	110	150	188	232	315
Core Net Profit	111	150	188	232	315

Exhibit 13. Balance Sheet

Year to 31 Dec (IDRbn)	2017A	2018A	2019F	2020F	2021F
Cash & cash equivalent	350	240	368	397	489
Receivables	871	1,023	1,038	1,210	1,368
Inventory	385	519	500	589	669
Other Curr. Asset	65	62	69	66	68
Fixed assets - Net	1,247	1,424	1,641	1,793	1,909
Other non-curr.asset	195	192	192	192	192
Total asset	3,238	3,592	3,940	4,379	4,826
CT Dobt	546	588	F00	693	751
ST Debt	540	388	580	093	/51
Payables	432	545	742	873	992
Other Curr. Liabilities	108	183	183	183	183
Long Term Debt	20	4	9	8	10
Other LT. Liabilities	77	85	82	83	82
Total Liabilities	1,182	1,405	1,596	1,839	2,019
Shareholder'sFunds	2,018	2,159	2,317	2,511	2,780
Minority interests	37	28	28	28	28
Total Equity & Liabilities	3,238	3,592	3,940	4,379	4,826



Exhibit 14. Cash Flow

Year to 31 Dec (IDRbn)	2017A	2018A	2019F	2020F	2021F
Net income	110	150	188	232	315
Depreciation and Amort.	25	39	43	48	52
Change in Working Capital	132	(173)	201	(130)	(119)
OtherOper. Cash Flow	34	123	35	51	50
Operating Cash Flow	301	139	468	200	298
Capex	(50)	(216)	(261)	(200)	(169)
Others Inv. Cash Flow	0	7	14	15	19
Investing Cash Flow	(50)	(209)	(246)	(184)	(150)
Net change in debt	(213)	25	(3)	111	61
New Capital	33	14	0	0	0
Dividend payment	(36)	(39)	(30)	(38)	(46)
Other Fin. Cash Flow	(70)	(56)	(57)	(62)	(70)
Financing Cash Flow	(286)	(55)	(90)	12	(56)
Net Change in Cash	(35)	(125)	132	27	92
Cash - begin of the year	377	350	240	368	397
Cash - end of the year	350	240	368	397	489

Exhibit 15. Key Ratios

Year to 31 Dec	2017A	2018A	2019F	2020F	2021F
Growth (%)					
Sales	(9.5)	14.3	20.2	15.0	12.6
EBITDA	(21.4)	29.8	23.2	20.0	29.5
Operating profit	(21.9)	26.3	25.4	21.4	32.0
Net profit	(38.9)	35.9	25.1	23.7	35.6
Profitability (%)					
Gross margin	42.1	45.5	45.1	45.0	45.2
EBITDA margin	6.7	7.6	7.8	8.2	9.4
Operating margin	5.9	6.5	6.8	7.2	8.4
Net margin	3.5	4.2	4.3	4.7	5.6
ROAA	3.4	4.4	5.0	5.6	6.8
ROAE	5.6	7.2	8.4	9.6	11.9
Leverage					
Net Gearing (x)	0.1	0.2	0.1	0.1	0.1
Interest Coverage (x)	2.7	4.2	5.2	5.8	6.7

Source: KINO, Danareksa Estimates

DISCLAIMER

The information contained in this report has been taken from sources which we deem reliable. However, none of P.T. Danareksa Sekuritas and/or its affiliated companies and/or their respective employees and/or agents makes any representation or warranty (express or implied) or accepts any responsibility or liability as to, or in relation to, the accuracy or completeness of the information and opinions contained in this report or as to any information contained in this report or any other such information or opinions remaining unchanged after the issue thereof.

We expressly disclaim any responsibility or liability (express or implied) of P.T. Danareksa Sekuritas, its affiliated companies and their respective employees and agents whatsoever and howsoever arising (including, without limitation for any claims, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a results of acting in reliance upon the whole or any part of the contents of this report and neither P.T. Danareksa Sekuritas, its affiliated companies or their respective employees or agents accepts liability for any errors, omissions or mis-statements, negligent or otherwise, in the report and any liability in respect of the report or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expresses disclaimed.

The information contained in this report is not be taken as any recommendation made by P.T. Danareksa Sekuritas or any other person to enter into any agreement with regard to any investment mentioned in this document. This report is prepared for general circulation. It does not have regards to the specific person who may receive this report. In considering any investments you should make your own independent assessment and seek your own professional financial and legal advice.